Has Stephanie Hart received payments from drug or device companies?

Yes. Drug and device makers reported $20,135 in general payments to Stephanie Hart across 679 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephanie Hart did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephanie Hart come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephanie Hart

Nurse Practitioner · Post Falls, IDNPI 1659692200

Payments from drug & device makers

$20,135in general payments, 2019–2025

Across 679 payments — averaging $29.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$3K
Amgen$2K
E.r. Squibb & Sons, L.L.C.$2K
Johnson & Johnson$1K
Pfizer$1K
Novartis$975
plus $10K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	35	$3,292
Amgen	12	$1,884
E.r. Squibb & Sons, L.L.C.	57	$1,796
Johnson & Johnson	48	$1,198
Pfizer	52	$1,013
Novartis	74	$975
Seagen Inc.	16	$843
Bristol Myers Squibb	37	$629
Regeneron Healthcare Solutions, Inc.	24	$574
Genentech USA, Inc.	30	$525
AbbVie	16	$496
AVEO Pharmaceuticals, Inc.	16	$486
Astellas Pharma US Inc	11	$395
Exelixis Inc.	24	$394
Sanofi	11	$372
Incyte Corporation	10	$351
GSK	20	$337
Boehringer Ingelheim	12	$321
Lilly USA, LLC	14	$309
Eisai Inc.	14	$287
Beigene USA, Inc.	9	$265
Bayer	10	$244
Daiichi Sankyo Inc.	4	$188
Takeda Pharmaceuticals U.S.A., Inc.	7	$182
Gilead	7	$154
Galvanize Therapeutics, Inc	1	$145
Janssen Scientific Affairs, LLC	1	$140
Adaptive Biotechnologies Corporation	7	$140
Jazz Pharmaceuticals Inc.	6	$130
Array Biopharma Inc	7	$115
Sumitomo Pharma America, Inc.	5	$109
Ipsen Biopharmaceuticals, Inc	6	$107
Servier Pharmaceuticals LLC	5	$104
Myriad Genetic Laboratories, Inc.	4	$98
Acrotech Biopharma Inc.	4	$94
Spectrum Pharmaceuticals Inc.	3	$84
Genmab U.S., Inc.	3	$76
ADC Therapeutics America, Inc.	4	$74
Taiho Oncology, Inc.	3	$72
Puma Biotechnology, Inc.	4	$71
Pharmacosmos Therapeutics Inc.	3	$70
Springworks Therapeutics, Inc.	3	$69
EMD Serono, Inc.	3	$58
Pharmacyclics LLC, An Abbvie Company	2	$53
Progenics Pharmaceuticals, Inc.	2	$53
Stemline Therapeutics Inc.	2	$52
Blueprint Medicines Corporation	2	$51
Sun Pharmaceutical Industries Inc.	2	$51
Immunocore Limited	1	$49
Rigel Pharmaceuticals, Inc.	2	$49
Beone Medicines USA, Inc.	2	$44
Accord Healthcare, Inc.	2	$42
Sobi, Inc	1	$39
Mirati Therapeutics, Inc.	2	$38
AstraZeneca	1	$34
Dendreon Pharmaceuticals LLC	1	$30
CTI Biopharma Corp.	1	$28
Menarini Silicon Biosystems, Inc.	1	$26
Fennec Pharmaceuticals, Inc.	1	$24
Azurity Pharmaceuticals, Inc.	1	$23

How this compares

$20,135 in reported general payments places this provider in the 95th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho →

Medicare billing

Part B allowed, 2024

$48,332

Medicare patients

Services billed

2,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Other nurse practitioner in Post Falls